MERCURIC
A Phase Ib/II study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor PF-02341066 in KRASMT and KRASWT (with aberrant c-MET) Colorectal Cancer Patients
| Coordinatore | QUEEN'S UNIVERSITY BELFAST
Organization address
address: University Road contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Sito del progetto | http://mercuric.eu/ |
| Totale costo | 8˙096˙788 € |
| EC contributo | 5˙999˙994 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-12-01 - 2020-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
QUEEN'S UNIVERSITY BELFAST
Organization address
address: University Road contact info |
UK (BELFAST) | coordinator | 415˙289.88 |
| 2 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 1˙486˙544.38 |
| 3 |
UNIVERSITA DEGLI STUDI DI TORINO
Organization address
address: Via Giuseppe Verdi 8 contact info |
IT (TORINO) | participant | 711˙319.00 |
| 4 |
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
Organization address
address: 3 Avenue Victoria contact info |
FR (PARIS) | participant | 659˙994.44 |
| 5 |
BELFAST HEALTH AND SOCIAL CARE TRUST
Organization address
address: "Saintfield Road, Knockbracken Healthcare Park" contact info |
UK (BELFAST) | participant | 433˙308.82 |
| 6 |
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON
Organization address
city: Barcelona contact info |
ES (Barcelona) | participant | 431˙625.22 |
| 7 |
UNIVERSITAIR ZIEKENHUIS ANTWERPEN
Organization address
address: WILRIJKSTRAAT 10 contact info |
BE (EDEGEM) | participant | 430˙946.28 |
| 8 |
ROYAL COLLEGE OF SURGEONS IN IRELAND
Organization address
address: Saint Stephen's Green 123 contact info |
IE (DUBLIN) | participant | 330˙183.09 |
| 9 |
VELINDRE NATIONAL HEALTH SERVICE TRUST
Organization address
address: Parc Nantgarw-Charnwood Court 2 contact info |
UK (CARDIFF) | participant | 330˙183.09 |
| 10 |
UNIVERSITE PARIS DESCARTES
Organization address
address: Rue de l'Ecole de Medecine 12 contact info |
FR (PARIS) | participant | 210˙200.00 |
| 11 |
Masarykova univerzita
Organization address
address: Zerotinovo namesti 9 contact info |
CZ (BRNO STRED) | participant | 200˙595.00 |
| 12 |
MULTIPLICOM NV
Organization address
address: GALILEILAAN 18 contact info |
BE (NIEL) | participant | 193˙880.20 |
| 13 |
PINTAIL LTD
Organization address
address: SPRINGHILL AVENUE 77 contact info |
IE (BLACKROCK) | participant | 165˙925.20 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Colorectal cancer (CRC) is the 3rd most common cancer in Europe, and with approximately 200,000 deaths per year, it remains the 2nd most common cause of cancer death. More than half of all CRC patients develop distant metastases and have 5-year overall survival (OS) of less than 5% because of ineffective treatments. Increased understanding of cancer biology, coupled with the implementation of “omics”-based approaches, has revealed that cancer must be considered a heterogeneous disease. Historically, “one-size-fits-all” approaches have been standard practice in CRC treatment, but with the increased understanding of the molecular/genetic heterogeneity of CRC, it is clear that novel treatments must be developed and tested in selected subgroups to maximize the benefit of these new developments. MErCuRIC is a multicentre phase Ib/II clinical trial which will assess a novel therapeutic strategy (combined treatment of a MEK inhibitor PD-0325901 with a MET inhibitor PF-02341066) to combat metastasis, improve survival and change current clinical practice for CRC patients with KRAS mutant (MT) and KRAS wild type (WT) (with aberrant c-MET) tumours. The consortium will go beyond the current state-of-the-art by (i) employing a novel treatment strategy targeting the biology of the disease and by (ii) using next generation sequencing (NGS) and ‘xenopatients’ to identify CRC patient subgroups who will maximally benefit from this novel treatment strategy.'